These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3137685)

  • 21. Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis.
    Martin U; Fischer S; Kohnert U; Opitz U; Rudolph R; Sponer G; Stern A; Strein K
    Thromb Haemost; 1991 May; 65(5):560-4. PubMed ID: 1908140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of sustained patency after clot-selective coronary thrombolysis with Hybrid-B, a genetically engineered plasminogen activator with a prolonged biological half-life.
    Weinheimer CJ; James HL; Kalyan NK; Wilhelm J; Lee SG; Hung PP; Sobel BE; Bergmann SR
    Circulation; 1991 Apr; 83(4):1429-36. PubMed ID: 1901531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver.
    Tanswell P; Heinzel G; Greischel A; Krause J
    J Pharmacol Exp Ther; 1990 Oct; 255(1):318-24. PubMed ID: 2120422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction.
    Koster RW; Cohen AF; Kluft C; Kasper FJ; van der Wouw PA; Weatherley BC
    Clin Pharmacol Ther; 1991 Sep; 50(3):267-77. PubMed ID: 1914361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Turnover of human tissue plasminogen activator (tPA) in rabbits.
    Beebe DP; Aronson DL
    Thromb Res; 1986 Sep; 43(6):663-74. PubMed ID: 3094193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Recombinant tissue-type plasminogen activator: pharmacokinetics and effect on the hemostasis system of the human].
    Seifried E; Böck F; Tanswell P; Rijken DC; Kluft C; Heimpel H
    Klin Wochenschr; 1988; 66 Suppl 12():40-9. PubMed ID: 2450222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration.
    Witt W; Maass B; Baldus B; Hildebrand M; Donner P; Schleuning WD
    Circulation; 1994 Jul; 90(1):421-6. PubMed ID: 8026028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lysis of intracerebral hematoma with stereotactically implanted tissue plasminogen activator polymers in a rabbit model.
    Thai QA; Pradilla G; Legnani FG; Kretzer RM; Hsu W; Tamargo RJ
    J Neurosurg; 2006 Sep; 105(3):424-9. PubMed ID: 16961138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of human recombinant tissue-type plasminogen activator, administered intra-abdominally, in a rat peritonitis model.
    van Goor H; Bom VJ; van der Meer J; Sluiter WJ; Geerards S; van der Schaaf W; de Graaf JS; Bleichrodt RP
    Eur Surg Res; 1996; 28(4):287-94. PubMed ID: 8813653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats.
    Martin U; Sponer G; Strein K
    Drug Metab Dispos; 1993; 21(2):236-41. PubMed ID: 8097691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel heparin/protamine-based pro-drug type delivery system for protease drugs.
    Liang JF; Song H; Li YT; Yang VC
    J Pharm Sci; 2000 May; 89(5):664-73. PubMed ID: 10756332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys.
    Oikawa K; Kamimura H; Watanabe T; Miyamoto I; Higuchi S
    Thromb Res; 2001 Mar; 101(6):493-500. PubMed ID: 11323007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spatial orientation of tissue-type plasminogen activator bound at the melanoma cell surface.
    Bizik J; Trancikova D; Felnerova D; Verheijen JH; Vaheri A
    Biochem Biophys Res Commun; 1997 Oct; 239(1):322-8. PubMed ID: 9345318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction.
    Seifried E; Tanswell P; Ellbrück D; Haerer W; Schmidt A
    Thromb Haemost; 1989 Jun; 61(3):497-501. PubMed ID: 2508258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibrin affinity and clearance of t-PA deletion and substitution analogues.
    Johannessen M; Diness V; Pingel K; Petersen LC; Rao D; Lioubin P; O'Hara P; Mulvihill E
    Thromb Haemost; 1990 Feb; 63(1):54-9. PubMed ID: 2111048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
    Collen D; Stassen JM; Verstraete M
    J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits.
    Kamei M; Misono K; Lewis H
    Am J Ophthalmol; 1999 Dec; 128(6):739-46. PubMed ID: 10612511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Properties of a novel plasminogen activator (BM 06.022) produced in Escherichia coli.
    Martin U; Fischer S; Kohnert U; Lill H; Rudolph R; Sponer G; Stern A; Strein K
    Z Kardiol; 1990; 79 Suppl 3():167-70. PubMed ID: 2129142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.
    Tanswell P; Modi N; Combs D; Danays T
    Clin Pharmacokinet; 2002; 41(15):1229-45. PubMed ID: 12452736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.